Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — Probiodrug — H1 2016 Earnings Presentation
29 slides from Vivoryon Therapeutics's earnings presentation, Aug 30, 2016
Slide 1: Interim Report H1 2016
Interim Report H1 2016 Reporting period January – June 2016 Halle (Saale), 30 August 2016 Konrad Glund Hendrik Liebers Inge Lues Frank Weber CEO CFO CDO CMO
Slide 2: Important notice and disclaimer
Important notice and disclaimer This Presentation has been prepared and issued by Probiodrug AG (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any proj
Slide 3: Content
Content 1. Corporate introduction 2. Results January – June 2016 3. Outlook 4. Q & A 3
Slide 4: Investment highlights
Investment highlights Alzheimer’s Disease (“AD”) is the most common form of dementia, a 1 Alzheimer’s Disease: major burden, no cure devastating neurological disease affecting 46 million people world-wide* No cure or long-term beneficial treatment available No new drugs approved since 2007**
Slide 5: Longstanding track-record and renowned investor base
Longstanding track-record and renowned investor base Brief history Major investors (> 3%) 1997: Foundation, pioneered a new class of anti-diabetics (gliptins) – partnerships with Merck & Co, Ferring and Novartis 2004: Sold diabetes franchise to OSI Pharmaceuticals – proceeds partially returned t
Slide 6: Experienced management team
Experienced management team Management team Biography Konrad Glund, Co-founder of Probiodrug, CEO since 2006 PhD CEO Led development of DP 4 inhibitors, transactions with Merck, Novartis, OSI and Ferring Co-founder COO & VP business development OSI (Prosidion) in 2004-2006 Chairman of the >
Slide 7: Alzheimer's Disease: growing burden, no cure
Alzheimer's Disease: growing burden, no cure Worldwide dementia population will triple Alzheimer's Disease introduction in the next 30 years* Leading cause of dementia, ultimately CAGR leading to death +3% 132 Large burden on families 46 Growing cost for society Available treatments marginal
Slide 8: Original Abeta approach
Original Abeta approach Probiodrug targets toxic structures in Alzheimer's Disease Considerations* Most new drug treatments Most new drugs have focused on Abeta formation or Abeta/plaque clearance have targeted Abeta or plaques Therapies have focused on: 1. Reduction of Abeta formation 2. Cleara
Slide 9: Probiodrug's differentiated approach
Probiodrug’s differentiated approach Probiodrug targets toxic structures in Alzheimer's Disease Considerations* Probiodrug and others Most new drugs have focused on Abeta formation or Abeta/plaque clearance have progressed insights on Abeta and its role in AD Abeta has a physiological function
Slide 10: pGlu-Abeta - N-modified Abeta
pGlu-Abeta - N-modified Abeta Jawhar, S., Wirths, O., Bayer, T.A. JBC 286, 45, 2011 10
Slide 11: Focused proprietary pipeline
Focused proprietary pipeline Pre- Product Phase 1 Phase 2 clinical PQ912 Small molecule QC inhibitor Trial ongoing PBD-C06 pGlu-Abeta specific monoclonal antibody PQ1565 Small molecule QC inhibitor Clinical proof of concept 11
Slide 12: The Probiodrug Share
The Probiodrug Share KEY INFORMATION SHAREHOLDER (> 3%) ISIN: DE0007921835 WKN: 792183 Ticker Symbol: PBD Type of shares: Bearer shares Number of shares: 7,442,487 Stock exchange: Euronext Amsterdam Liquidity Provider: Kempen & Co. Listing Agent: Kempen & Co. First trading day: 27
Slide 13: Content
Content 1. Corporate introduction 2. Results January – June 2016 3. Outlook 4. Q & A 13
Slide 14: Key Highlights January to June 2016
Key Highlights January to June 2016 Announcement of favourable results of chronic toxicology studies with PQ912, Probiodrug`s ‘first- in-class’ Glutaminyl Cyclase (QC) inhibitor for the treatment of AD Annual Shareholders’ Meeting held on May 19, 2016 Key patents for Probiodrug’s pGlu-Abeta ta
Slide 15: Key financial figures January – June 2016 (according to IFRS)
Key financial figures January – June 2016 (according to IFRS) In EUR k, unless otherwise stated Jan - June 2016 Jan - June 2015 Jan - Dec 2015 Earnings, Financial and Net Assets Position 0 0 0 Revenues Operating loss -5,987 -6,177 -13,393 Net loss for the period -6,044 -6,233 -13,505 Equity (end of
Slide 16: Details of the Financial Results January – June 2016
Details of the Financial Results January – June 2016 (according to IFRS) Net loss net loss Net loss in line with expectations Operating loss primarily driven by R&D expenses, in particular the SAPHIR study Increase in operating expenses reflects operating loss EUR 5,987k primarily the developm
Slide 17: Operational Review (1)
Operational Review (1) Pipeline Update PQ912 PQ912 has been evaluated in rats and dogs in 4 weeks, 3 months and 6/9 months studies In April 2016 data of the chronic tox studies announced: No new findings were observed and the minimal to slight, non-adverse changes seen in both the 4-week and t
Slide 18: Operational Review (2)
Operational Review (2) Pipeline Update PQ912 In preceding Phase 1 study with healthy young and elderly volunteers shown to be safe, well tolerated and revealed high QC-inhibition SAPHIR is a randomized, double-blind multi-center Phase 2a study in early AD patients Led by internationally renown
Slide 19: Operational Review (3)
Operational Review (3) PBD-C06 Monoclonal antibody targeting pGlu-Abeta, while leaving non-toxic forms of Abeta untouched Currently in preclinical stage Successfully humanized and de-immunized For the first time for an anti-pGlu-Abeta-antibody approach PBD-C06 has not only shown the ability
Slide 20: Operational Review (4)
Operational Review (4) Publications/ Presentations March 2016: pGlu-Abeta Approaches being presented at 14th AAT Symposium on Advances in Alzheimer Therapy, Athens, Greece Presentation entitled “The pyroglutamate modification of toxic A-beta resulted in new therapeutic approaches: Inhibitors of
Slide 21: Operational Review (5)
Operational Review (5) IP January and June 2016: IP position further strengthened by important patent applications being granted: Japanese Patent Office has granted the company two important patents. 5.934.645 Heterocyclic derivatives as inhibitors of glutaminyl cyclase 5.930.573 cover the g
Slide 22: Corporate Review
Corporate Review Annual Shareholders’ Meeting 2016 on 19 May, 2016 All resolutions proposed by the Company’s Management and Supervisory Board were approved at the meeting including: Adoption of a resolution on the approval of the actions of the management board members for the financial year 201
Slide 23: Post Period Highlights
Post Period Highlights Eli Lilly presented data of LY3002813 its antibody targeting pGlu-Abeta At the Alzheimer’s Association International Conference 2016 (AAIC) held in Toronto in July 2016, Eli Lilly presented data from a patient trial of LY3002813, its antibody targeting pGlu- Abeta. LY30028
Slide 24: Content
Content 1. Corporate introduction 2. Results January – June 2016 3. Outlook 4. Q & A 24
Slide 25: Outlook 2016
Outlook 2016 Further preclinical and clinical testing of the development candidate PQ912, in particular completion of the first patient study in a Phase 2a trial in 2017 and the evaluation and design of a long -term treatment. Compiling further supporting data and securing intellectual property
Slide 26: Anticipated news flow (selection)
Anticipated news flow (selection) 2014 2015 2016 2017 First patient enrolled in PQ912 Phase 2a ✔ “SAPHIR” study at leading Alzheimer Center in Amsterdam PQ912 Phase 2a ✔ PQ912 results of long term tox studies SAPHIR results Additional data on Glutaminyl Cyclases ✔ (QCs) in AD published in Ac
Slide 27: Financial Calendar
Financial Calendar May 12th, 2016 Interim Management Statement Q1 2016 May 9th, 2016 Annual General Meeting of Shareholders in Berlin August 23rd, 2016 Interim Report, half year results 2016 November 10th, 2016 Interim Management Statement Q3 2016 27
Slide 28: Content
Content 1. Corporate introduction 2. Results January – June 2016 3. Outlook 4. Q & A 28
Slide 29: Q&A
probtodrug O&A probtodrug